Compare Sana Biotechnology Inc (SANA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Invesco S&P 500 Low Volatility ETF trades at $74.1. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPLV | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | — |
52-Week High | $5.92 | $77.97 |
52-Week Low | $2.68 | $70.30 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $74.55, down 0.25% on the day, with a bearish technical signal driven by moving averages. The ETF has underperformed the S&P 500, returning 5% versus 17%, due to sector overweights in Utilities, Real Estate, and Financials. Recent news highlights its role as a stability-focused option amid market volatility, with dividends scheduled for mid-2026.
The outlook for SPLV is neutral to cautious, offering defensive exposure but facing headwinds from unappealing growth-adjusted valuations and sector concentration risks. Investment appeal hinges on market volatility trends, while risks include prolonged underperformance if low-volatility sectors lag in a growth-oriented market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
